Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe immune weakness in rare mitochondrial disorders

NCT ID NCT06213103

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how mitochondrial diseases might weaken the immune system. Researchers will collect blood samples from 60 people with confirmed mitochondrial disorders and compare their immune cells and antibodies to healthy controls. The goal is to better understand these immune problems, which could help with diagnosis and lead to new treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could point toward new ways to diagnose or treat immune problems in people with mitochondrial diseases.
What could go wrong
This is an early observational study, not a treatment trial. It may not lead directly to new therapies, and the findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Patient cohort : Patient with moleculary proven mitochondrial disorder * Control cohort : People without moleculary proven mitochondrial disorder

Ages

6 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * General inclusion criteria: * Patient weighing more than 30kg * Person affiliated with or receiving a social security plan; * Patient-specific inclusion criteria: * Patient with molecularly proven primary mitochondrial disease * Free, informed, written consent signed by parental authority holders for minor patients and the investigator prior to any examination required by the research and oral and/or written assent by the participant (depending on age). * Free, informed consent signed by the patient's representative for adult patients under guardianship and the investigator prior to any examination required by the research. * Free, informed consent signed by the patient of legal age and the investigator prior to any examination required by the research * Specific inclusion criteria for controls: * Person who has been informed of the purpose of the study and person matched in age (+/- 5 years) and sex to a patient with primary mitochondrial disease at the time of sampling * Free, informed, and signed consent * Person with no known mitochondrial disease Exclusion Criteria: * Pregnant or breastfeeding women * Refusal to consent to participate in research, * Patients for whom molecular causes have not been formally identified (genetic analyses not performed, or no variant or variant of unknown significance after analysis).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mitochondrial disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

inborn mitochondrial metabolism disorder mitochondrial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mitochondrial disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Bordeaux

    RECRUITING

    Bordeaux, France

  • Hopital Toulouse

    NOT_YET_RECRUITING

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.